Skip to content

Search

Showing results for "clinical trials"

The Platform Trial In COVID-19 priming and BOOsting : The immunogenicity, reactogenicity, and safety of licensed COVID-19 vaccinations administered as a second booster in BNT162b2

PICOBOO is a randomised, adaptive trial evaluating the immunogenicity, reactogenicity, and safety of COVID-19 booster strategies. Here, we present data for second boosters among individuals aged 18-<50 and 50-<70 years old primed with BNT162b2 until Day (D) 84.

What is the optimal level of vitamin D?: Separating the evidence from the rhetoric

New evidence indicates that both high and low 25(OH)D levels may be associated with increased health risks.

AMEND study protocol: A case-control study to assess the long-term impact of invasive meningococcal disease in Australian adolescents and young adults

This study aims to address this evidence gap by assessing the clinical, physical, neurocognitive, economic and societal impact of invasive meningococcal disease

European Respiratory Society guidelines for the diagnosis of primary ciliary dyskinesia

Guideline to provide evidence-based recommendations on diagnostic testing for primary ciliary dyskinesia

Predicting disease progression in cystic fibrosis

Predicting disease progression in cystic fibrosis ABSTRACT Introduction: Progressive lung disease is the major cause of morbidity and mortality in

Long-term outcomes of childhood encephalitis in Australia: burden and predictors from the Australian childhood encephalitis (ACE) prospective multicentre cohort

Encephalitis is inflammation of the brain parenchyma with heterogenous aetiology and presentation. In children, it often leads to short-term residual neurological deficits, however clinical predictors of adverse long-term outcome are not fully understood.

A national harmonised data collection network for neurodevelopmental disorders: A transdiagnostic assessment protocol for neurodevelopment, mental health, functioning and well-being

Children with neurodevelopmental disorders share common phenotypes, support needs and comorbidities. Such overlap suggests the value of transdiagnostic assessment pathways that contribute to knowledge about research and clinical needs of these children and their families.

Dr Anita Campbell

Infectious Diseases Physician; Raine Clinician Postdoctoral Research Fellow; Deputy Head of the Wesfarmers Centre of Vaccines and Infectious Diseases; Clinical Senior Lecturer, School of Medicine, The University of Western Australia

Robust and Interpretable General Movement Assessment Using Fidgety Movement Detection

Fidgety movements occur in infants between the age of 9 to 20 weeks post-term, and their absence are a strong indicator that an infant has cerebral palsy. Prechtl's General Movement Assessment method evaluates whether an infant has fidgety movements, but requires a trained expert to conduct it. Timely evaluation facilitates early interventions, and thus computer-based methods have been developed to aid domain experts. 

Outcomes following intensive day rehabilitation for young people in Western Australia

Intensive rehabilitation aims to improve and maintain functioning in young people who experience disability due to illness or injury. Day rehabilitation may have advantages for families and healthcare systems over inpatient models of rehabilitation.